Convalescent Plasma to Stem Coronavirus (CSSC-001)

a study on COVID-19 Convalescence

Summary

Eligibility
for people ages 18 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at UC Davis UC Irvine UCLA UCSD
Dates
study started
estimated completion
Principal Investigator
by Edward Cachay, MD (ucsd)Judith Currier, MD (ucla)Don Forthal, MD (uci)
Photo of Edward Cachay
Edward Cachay

Description

Summary

Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.

Official Title

Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19

Details

This randomized, controlled, double-blinded phase 2 trial will assess the efficacy and safety of Anti- SARS-CoV-2 convalescent plasma as prophylaxis following exposure to COVID-19 (as defined in the inclusion criteria). Adults 18 years of age and older with high risk exposure as defined by CDC may participate. A total of 500 eligible subjects will be randomized in a 1:1 ratio to receive either high titer anti-SARS-CoV-2 plasma or control (SARS-CoV-2 non-immune plasma).

Keywords

Coronavirus Convalescence COVID-19 Coronavirus Infections Anti- SARS-CoV-2 Plasma SARS-CoV-2 non-immune Plasma High titer anti-SARS-CoV-2 plasma

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Subjects must be 18 years of age or older
  2. Close contact exposure (as defined by CDC guidelines) to person with COVID-19 within 96 hours of randomization (and 120 hours of receipt of plasma)

You CAN'T join if...

  1. Receipt of any blood product in past 120 days.
  2. Medical, psychiatric,cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance.
  3. Symptoms consistent with COVID-19 infection (fevers, acute onset cough, shortness of breath) at time of screening.
  4. Laboratory evidence of COVID-19 infection at time of screening.
  5. History or known laboratory evidence of previous COVID-19 infection.
  6. History of prior reactions to transfusion blood products.
  7. Inability to complete therapy with the study product within 24 hours after randomization.

Locations

  • University of California, San Diego accepting new patients
    La Jolla California 92093 United States
  • University of California, Los Angeles accepting new patients
    Los Angeles California 90095 United States
  • University of California, Irvine Health accepting new patients
    Orange California 92868 United States
  • University of California, Davis withdrawn
    Sacramento California 95817 United States

Lead Scientists at UC Health

  • Edward Cachay, MD (ucsd)
    I joined the University of California, San Diego in the Owen Clinic in 2007, having completed a fellowship in Infectious Diseases and a Master in Advanced Studies. During this time I have dedicated my professional time as a clinical teacher whose scholarly portfolio emphasized the management of HIV and its associated co-morbidities.
  • Judith Currier, MD (ucla)
    Professor, Medicine. Authored (or co-authored) 213 research publications.
  • Don Forthal, MD (uci)
    Professor, Medicine. Authored (or co-authored) 108 research publications.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Johns Hopkins University
ID
NCT04323800
Phase
Phase 2
Study Type
Interventional
Last Updated